ArticleMemorias do Instituto Oswaldo Cruz2026
Genome mining and characterisation of biosynthetic clusters in Aspergillus japonicus isolated from the Amazon rainforest.
Article in Memorias do Instituto Oswaldo Cruz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn light of the biotechnological potential demonstrated by Aspergillus species and, considering the great need for further research into the search for new sources of active molecules and the biodiversity of these microorganisms occurring in the Amazon region.
objectivesThis research aimed to investigate the biotechnological potential of the fungus Aspergillus japonicus Amazon Fungi Collection (CFAM) 0234, a fungal strain isolated from Amazonian soil and stored in the CFAM.
methodsFor this purpose, the Aspergillus species was investigated through comparative genomic analysis and antimicrobial activity assays.
findingsGenome sequencing revealed a fragmented assembly (72.67 Mbp, N50 = 152 kbp) containing 106 biosynthetic clusters (BGCs), surpassing the reference strain CBS 114.51 (57 BGCs). Among the clusters identified, NRPS, PKS type I and hybrid NRPS-PKS systems stood out, including clusters exclusive to betalactones and isocyanides, potentially involved in the synthesis of β-lactam antibiotics and innovative metabolites. BiG-SCAPE analysis identified 63 BGC families unique to CFAM 0234, suggesting evolutionary adaptations to the competitive environment of the Amazon. Biological assays demonstrated selective antimicrobial activity of the ethyl acetate extract against Escherichia coli, Shigella sonnei and Sthapylococcus aureus (MRSA), with inhibition halos ranging from 8 mm to 6 mm in diameter, pathogens classified as priorities for research into new antibiotics. The correlation between predicted BGCs and antimicrobial activity reinforces the strain's biotechnological potential. Despite the fragmentation of the genome, the high completeness assessed by BUSCO (98.5%) confirms the quality of the assembly, while the detection of single nucleotide polymorphisms (SNPs) in regulatory regions and rearrangements close to BGCs suggests evolutionary pressure for metabolic diversification. The lack of correspondence with the minimum information about a biosynthetic gene cluster (MIBiG) bank and the limitations of crude extracts highlight the need for complementary techniques, such as long-read sequencing (Oxford Nanopore) and metabolomic analysis [liquid chromatography-mass espectrometry (LC-MS)], to link clusters to active metabolites. MAIN
conclusionsAspergillus japonicus CFAM 0234 represents a promising microbial resource for bioprospecting in the Amazon, offering relevant genomic and chemical insights for the development of new antimicrobial agents. Future studies will focus on the purification of compounds and activation of silent BGCs, aiming at sustainable pharmaceutical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.